全球蛋白質治療市場規模、佔有率、成長分析、按產品類型、按應用、按治療領域 - 行業預測，2024-2031 年

2022年全球蛋白質治療市場規模為65.7億美元，從2023年的69.6億美元成長到2031年的111億美元，在預測期間（2024-2031年）預計複合年成長率為6%。

由於生物製藥領域的不斷擴大和慢性病盛行率的上升，蛋白質治療市場正在經歷顯著成長。單株抗體、胰島素和疫苗等蛋白質治療藥物在各種疾病的治療中繼續發揮重要作用。生物技術的進步以及基於蛋白質的創新配方的出現，為市場擴張做出了重大貢獻。此外，儘管存在高製造成本和監管障礙等挑戰，但個人化醫療和標靶治療策略的日益採用也推動了需求。雖然北美仍然佔據主導地位，但在醫療基礎設施改善和患者數量迅速增加的推動下，亞太地區正在迅速崛起。主要趨勢包括尋找新的治療標靶以及將先進技術整合到蛋白質治療開發中。

目錄

執行摘要

• 市場概況
• 命運之輪

調查方法

• 資訊採購
• 次要和主要資料來源
• 市場規模估算
• 市場假設與限制

母市場分析

• 市場概況
• 市場規模
• 市場動態
  • 促進因素
  • 機會
  • 抑制因素
  • 任務

主要市場考察

• 技術分析
• 價格分析
• 供應鏈分析
• 價值鏈分析
• 市場生態系統
• 智慧財產權分析
• 貿易分析
• Start-Ups分析
• 原料分析
• 創新矩陣
• 研發線產品分析
• 總體經濟指標
• 主要投資分析
• 關鍵成功因素
• 競爭程度

市場動態及展望

• 市場動態
  • 促進因素
  • 機會
  • 抑制因素
  • 任務
• 監管環境
• 波特的分析
• 對未來中斷的特殊考慮

全球蛋白質療法市場：按產品類型

• 市場概況
• 單株抗體
• 胰島素
• 疫苗
• 生長激素
• 凝血因子
• 酵素替代療法

全球蛋白質治療市場：依應用分類

• 市場概況
• 腫瘤學
• 血液學
• 免疫學
• 代謝紊亂
• 心血管疾病
• 其他

全球蛋白質治療市場：按治療領域

• 市場概況
• 癌症
• 糖尿病
• 感染疾病
• 自體免疫疾病
• 遺傳疾病
• 其他

全球蛋白質治療市場規模：按地區分類

• 市場概況
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 歐洲其他地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中東和非洲 (MEA)
  • 海灣合作理事會國家
  • 南非
  • 其他中東/非洲

競爭格局

• 前5名企業對比
• 主要企業市場定位（2021年）
• 主要市場參與者所採取的策略
• 關鍵成功策略
• 近期市集活動
• 主要企業市場佔有率（2021年）

主要企業簡介

• Amgen Inc.（US）
• AbbVie Inc.（US）
• Roche Diagnostics（Switzerland）
• Eli Lilly and Company（US）
• Johnson & Johnson（US）
• Pfizer Inc.（US）
• F. Hoffmann-La Roche Ltd（Switzerland）
• Novo Nordisk A/S（Denmark）
• Merck & Co., Inc.（US）
• Celgene Corporation（US）
• GlaxoSmithKline PLC（UK）
• Gilead Sciences, Inc.（US）
• Biogen Inc.（US）
• AstraZeneca PLC（UK）
• Takeda Pharmaceutical Company Limited（Japan）
• Abbott Laboratories（US）
• Bayer AG（Germany）
• Alexion Pharmaceuticals Inc.（US）
• Novartis AG（Switzerland）
• Sanofi（France）

Global Protein Therapeutics Market size was valued at USD 6.57 billion in 2022 and is poised to grow from USD 6.96 billion in 2023 to USD 11.10 billion by 2031, growing at a CAGR of 6% during the forecast period (2024-2031).

The Protein Therapeutics market is experiencing significant growth attributed to the expanding realm of biopharmaceuticals and the rising prevalence of chronic illnesses. Monoclonal antibodies, insulin, and vaccines, among other protein therapeutics, continue to serve as crucial components in treating various medical conditions. Technological advancements in biotechnology, alongside the emergence of innovative protein-based formulations, contribute significantly to market expansion. Moreover, the increasing adoption of personalized medicine and targeted treatment strategies drives demand, despite challenges such as high production costs and regulatory hurdles. While North America remains dominant, the Asia-Pacific region is rapidly emerging, propelled by improved healthcare infrastructure and burgeoning patient populations. Key trends include the exploration of novel therapeutic targets and the integration of advanced technologies into protein therapy development.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Protein Therapeutics Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Protein Therapeutics Market Segmental Analysis

The global Protein Therapeutics market is segmented into four major segments i.e. by Product Type, Application, Therapeutic Area, and region. Based on Type, it is divided into Monoclonal Antibodies, Insulin, Vaccines, Growth Hormones, Blood Clotting Factors, Enzyme Replacement Therapies. Based on Application, it is bifurcated as Oncology, Hematology, Immunology, Metabolic Disorders, Cardiovascular Disorders, Others. Based on Therapeutic Area it is segregated into Cancer, Diabetes, Infectious Diseases, Autoimmune Disorders, Genetic Disorders, and Others. Based on region, the market is segmented into North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.

Drivers of the Global Protein Therapeutics Market

The increasing incidence of chronic ailments and intricate medical conditions underscores the significance of protein-based therapies, offering tailored and efficient solutions. The adaptability of protein therapeutics, encompassing monoclonal antibodies and other biologics, enables precise interventions across diverse therapeutic domains such as oncology, immunology, and metabolic disorders. Moreover, advancements in biotechnology and genetic engineering have paved the way for the creation of innovative and more potent protein therapeutics. As the demand for personalized medicine rises and the need for biopharmaceuticals with reduced side effects grows, there is a burgeoning inclination towards the adoption of protein-based treatments.

Restraints in the Global Protein Therapeutics Market

One of the main obstacles in the marketplace is the high cost linked with the development, production, and introduction of protein-based therapies. The intricate manufacturing processes and the requirement for sophisticated technologies contribute to inflated expenses, restricting accessibility, particularly in less affluent regions. Moreover, regulatory intricacies and rigorous approval procedures create hurdles, prolonging the time-to-market for protein therapeutics. Concerns regarding immunogenicity, wherein the patient's immune system may react to the therapeutic protein, further complicate matters.

Market Trends of the Global Protein Therapeutics Market

There is a noticeable shift towards personalized treatment in healthcare, particularly evident in the development of targeted protein therapeutics customized to individual patient characteristics. This trend is supported by advancements in next-generation biologics like antibody-drug conjugates and bispecific antibodies, offering more potent and adaptable therapeutic options. Additionally, advancements in protein engineering are enabling the creation of novel and optimized protein structures, thereby enhancing therapeutic effectiveness. The exploration of alternative delivery routes such as subcutaneous and oral administration is becoming increasingly popular, offering improved patient convenience.

Table of Contents

Executive Summary

• Market Overview
• Wheel of Fortune

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Parent Market Analysis

• Market Overview
• Market Size
• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges

Key Market Insights

• Technology Analysis
• Pricing Analysis
• Supply Chain Analysis
• Value Chain Analysis
• Ecosystem of the Market
• IP Analysis
• Trade Analysis
• Startup Analysis
• Raw Material Analysis
• Innovation Matrix
• Pipeline Product Analysis
• Macroeconomic Indicators
• Top Investment Analysis
• Key Success Factor
• Degree of Competition

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Regulatory Landscape
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers
• Skyquest Special Insights on Future Disruptions
  • Political Impact
  • Economic Impact
  • Social Impact
  • Technical Impact
  • Environmental Impact
  • Legal Impact

Global Protein Therapeutics Market by Product Type

• Market Overview
• Monoclonal Antibodies
• Insulin
• Vaccines
• Growth Hormones
• Blood Clotting Factors
• Enzyme Replacement Therapies

Global Protein Therapeutics Market by Application

• Market Overview
• Oncology
• Hematology
• Immunology
• Metabolic Disorders
• Cardiovascular Disorders
• Others

Global Protein Therapeutics Market by Therapeutic Area

• Market Overview
• Cancer
• Diabetes
• Infectious Diseases
• Autoimmune Disorders
• Genetic Disorders
• Others

Global Protein Therapeutics Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2021
• Strategies Adopted by Key Market Players
• Top Winning Strategies
  • By Development
  • By Company
  • By Year
• Recent Activities in the Market
• Key Companies Market Share (%), 2021

Key Company Profiles

• Amgen Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Diagnostics (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novo Nordisk A/S (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Celgene Corporation (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline PLC (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca PLC (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alexion Pharmaceuticals Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments